Search papers, labs, and topics across Lattice.
1
1
0
2
It is demonstrated that ex vivo CRISPR/Cas9 excision of the GAA expansion in hematopoietic stem and progenitor cells (HSPCs) provides durable, systemic therapy for Friedreich's ataxia and is established as a one-time, disease-modifying therapy for FRDA.